Skip to main content
Erschienen in: Breast Cancer 1/2011

01.01.2011 | Special Feature

Pilot study of radiofrequency ablation therapy without surgical excision for T1 breast cancer: evaluation with MRI and vacuum-assisted core needle biopsy and safety management

verfasst von: Naohito Yamamoto, Hiroshi Fujimoto, Rikiya Nakamura, Manabu Arai, Atsushi Yoshii, Sachiko Kaji, Makiko Itami

Erschienen in: Breast Cancer | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

There is increasing demand for minimally invasive treatments for small breast cancer mainly because of the desire for better cosmetic results. Although radiofrequency ablation (RFA) is an attractive approach as a local control method for small breast cancer, the problems of histological effectiveness and safety management remain.

Methods

A total of 29 patients including one patient with bilateral breast cancer were enrolled in this study. The mean tumor size of 30 breasts was 12.8 mm (range 5–19 mm). Under general anesthesia, RFA was performed with a Cool-tip RF system (Valleylab, Boulder, CO, USA) after sentinel lymph node biopsy. Postoperative evaluation with magnetic resonance imaging (MRI) and vacuum-assisted core needle biopsy was done 3–4 weeks after RFA before radiotherapy. Ablated tumors were evaluated with hematoxylin–eosin (H&E) and nicotinamide adenine dinucleotide (NADH)-diaphorase staining. If needed, adjuvant chemo and/or endocrine therapy was performed.

Results

All patients except one completed one session of RFA. The mean temperature near the center of the tumors was 89.6°C (range 78–100°C). Postoperative MRI showed the ablated zone clearly in all patients. MRI revealed no hypervascularity of the tumors in the ablated zone. Evaluation with H&E staining of the tumors showed remarkable degenerative changes in only three patients. NADH-diaphorase staining showed no viable tumor tissue in 24 patients out of 26 examined. Three patients received small diameter grade 3 skin burns, two on the outside of the thigh from the grounding pad and one on the breast skin. One patient had a breast lesion like a chronic granulomatous mastitis resulting from overreaction of the ablated zone.

Conclusions

RFA therapy appeared relevant and applicable for patients with small breast cancer. Because small skin burns were observed as adverse events, close attention should be paid in the course of the RFA procedure.
Literatur
1.
Zurück zum Zitat Jeffrey SS, Birdwell RL, Ikeda DM, Daniel BL, Nowels KW, Dirbas FM, et al. Radiofrequency ablation of breast cancer: first report of an emerging technology. Arch Surg. 1999;134:1064–8.CrossRefPubMed Jeffrey SS, Birdwell RL, Ikeda DM, Daniel BL, Nowels KW, Dirbas FM, et al. Radiofrequency ablation of breast cancer: first report of an emerging technology. Arch Surg. 1999;134:1064–8.CrossRefPubMed
2.
Zurück zum Zitat Izzo F, Thomas R, Delrio P, Rinaldo M, Vallone P, DeChiara A, et al. Radiofrequency ablation in patients with primary breast carcinoma. A pilot study in 26 patients. Cancer. 2001;92:2036–44.CrossRefPubMed Izzo F, Thomas R, Delrio P, Rinaldo M, Vallone P, DeChiara A, et al. Radiofrequency ablation in patients with primary breast carcinoma. A pilot study in 26 patients. Cancer. 2001;92:2036–44.CrossRefPubMed
3.
Zurück zum Zitat Mirza AN, Fornage BD, Sneige N, Kuerer HM, Newman LA, Ames FC, et al. Radiofrequency ablation of solid tumors. Cancer J. 2001;7:95–102.PubMed Mirza AN, Fornage BD, Sneige N, Kuerer HM, Newman LA, Ames FC, et al. Radiofrequency ablation of solid tumors. Cancer J. 2001;7:95–102.PubMed
4.
Zurück zum Zitat Singletary SE. Feasibility of radiofrequency ablation for primary breast cancer. Breast Cancer. 2003;10:4–9.CrossRefPubMed Singletary SE. Feasibility of radiofrequency ablation for primary breast cancer. Breast Cancer. 2003;10:4–9.CrossRefPubMed
5.
Zurück zum Zitat Noguchi M, Earashi M, Fujii H, Yokoyama K, Harada K, Tsuneyama K. Radiofrequency ablation of small breast cancer followed by surgical resection. J Surg Oncol. 2006;93:120–8.CrossRefPubMed Noguchi M, Earashi M, Fujii H, Yokoyama K, Harada K, Tsuneyama K. Radiofrequency ablation of small breast cancer followed by surgical resection. J Surg Oncol. 2006;93:120–8.CrossRefPubMed
6.
Zurück zum Zitat Imoto S, Wada N, Sakemura N, Hasebe T, Murata Y. Feasibility study on radiofrequency ablation followed by partial mastectomy for stage I breast cancer patients. Breast. 2009;18:130–4.CrossRefPubMed Imoto S, Wada N, Sakemura N, Hasebe T, Murata Y. Feasibility study on radiofrequency ablation followed by partial mastectomy for stage I breast cancer patients. Breast. 2009;18:130–4.CrossRefPubMed
7.
Zurück zum Zitat Elliott RI, Rice PB, Suits JA, Ostrowe AJ, Head JF. Radiofrequency ablation of a stereotactically localized nonpalpable breast carcinoma. Am Surg. 2002;68:1–5.PubMed Elliott RI, Rice PB, Suits JA, Ostrowe AJ, Head JF. Radiofrequency ablation of a stereotactically localized nonpalpable breast carcinoma. Am Surg. 2002;68:1–5.PubMed
8.
Zurück zum Zitat Burak WE Jr, Agnese DM, Povoski SP, Yanssens TL, Bloom KJ, Wakely PE, et al. Radiofrequency ablation of invasive breast carcinoma followed by delayed surgical excision. Cancer. 2003;98:1369–76.CrossRefPubMed Burak WE Jr, Agnese DM, Povoski SP, Yanssens TL, Bloom KJ, Wakely PE, et al. Radiofrequency ablation of invasive breast carcinoma followed by delayed surgical excision. Cancer. 2003;98:1369–76.CrossRefPubMed
9.
Zurück zum Zitat Hayashi AH, Silver SF, van der Westhuizen NG, Donald JC, Parker C, Fraser S, et al. Treatment of invasive breast carcinoma with ultrasound-guided radiofrequency ablation. Am J Surg. 2003;185:429–35.CrossRefPubMed Hayashi AH, Silver SF, van der Westhuizen NG, Donald JC, Parker C, Fraser S, et al. Treatment of invasive breast carcinoma with ultrasound-guided radiofrequency ablation. Am J Surg. 2003;185:429–35.CrossRefPubMed
10.
Zurück zum Zitat Susini T, Nori J, Olivieri S, Livi L, Bianchi S, Mangialavori G, et al. Radiofrequency ablation for minimally invasive treatment of breast carcinoma, a pilot study in elderly inoperable patients. Gynecol Oncol. 2007;104(2):304–10.CrossRefPubMed Susini T, Nori J, Olivieri S, Livi L, Bianchi S, Mangialavori G, et al. Radiofrequency ablation for minimally invasive treatment of breast carcinoma, a pilot study in elderly inoperable patients. Gynecol Oncol. 2007;104(2):304–10.CrossRefPubMed
11.
Zurück zum Zitat Marcy PY, Magné N, Castadot P, Bailet C, Namer M. Ultrasound-guided percutaneous radiofrequency ablation in elderly breast cancer patients: preliminary institutional experience. Br J Radiol. 2007;80:267–73.CrossRefPubMed Marcy PY, Magné N, Castadot P, Bailet C, Namer M. Ultrasound-guided percutaneous radiofrequency ablation in elderly breast cancer patients: preliminary institutional experience. Br J Radiol. 2007;80:267–73.CrossRefPubMed
12.
Zurück zum Zitat Noguchi M. Radiofrequency ablation treatment for breast cancer to meet the next challenge: how to treat primary breast tumor without surgery. Breast Cancer. 2003;10:203–5. Noguchi M. Radiofrequency ablation treatment for breast cancer to meet the next challenge: how to treat primary breast tumor without surgery. Breast Cancer. 2003;10:203–5.
13.
Zurück zum Zitat Earashi M, Noguchi M, Motoyoshi A, Fujii H. Radiofrequency ablation therapy for small breast cancer followed by immediate surgical resection or delayed mammotome excision. Breast Cancer. 2007;14:39–47.CrossRefPubMed Earashi M, Noguchi M, Motoyoshi A, Fujii H. Radiofrequency ablation therapy for small breast cancer followed by immediate surgical resection or delayed mammotome excision. Breast Cancer. 2007;14:39–47.CrossRefPubMed
14.
Zurück zum Zitat Oura S, Tamaki T, Hirai I, Yoshimasu T, Ohta F, Nakamura R, et al. Radiofrequency ablation therapy in patients with breast cancers two centimeters or less in size. Breast Cancer. 2007;14:48–54.CrossRefPubMed Oura S, Tamaki T, Hirai I, Yoshimasu T, Ohta F, Nakamura R, et al. Radiofrequency ablation therapy in patients with breast cancers two centimeters or less in size. Breast Cancer. 2007;14:48–54.CrossRefPubMed
15.
Zurück zum Zitat Nagashima T, Sakakibara M, Sangai T, Kazama T, Fujimoto H, Miyazaki M. Surrounding rim formation and reduction in size after radiofrequency ablation for primary breast cancer. Jpn J Radial. 2009;27:197–204.CrossRef Nagashima T, Sakakibara M, Sangai T, Kazama T, Fujimoto H, Miyazaki M. Surrounding rim formation and reduction in size after radiofrequency ablation for primary breast cancer. Jpn J Radial. 2009;27:197–204.CrossRef
16.
Zurück zum Zitat Fornage BD, Sneige N, Ross MI, Mirza AN, Kuerer HM, Edeiken BS, et al. Small breast cancer treated with US-guided radiofrequency ablation. Radiology. 2004;231:215–24.CrossRefPubMed Fornage BD, Sneige N, Ross MI, Mirza AN, Kuerer HM, Edeiken BS, et al. Small breast cancer treated with US-guided radiofrequency ablation. Radiology. 2004;231:215–24.CrossRefPubMed
17.
Zurück zum Zitat Manenti G, Bolacchi F, Perretta T, Cossu E, Pistolese CA, Buonomo OC, et al. Small breast cancers: in vivo percutaneous US-guided radiofrequency ablation with dedicated cool-tip radiofrequency system. Radiology. 2009;251:339–46.CrossRefPubMed Manenti G, Bolacchi F, Perretta T, Cossu E, Pistolese CA, Buonomo OC, et al. Small breast cancers: in vivo percutaneous US-guided radiofrequency ablation with dedicated cool-tip radiofrequency system. Radiology. 2009;251:339–46.CrossRefPubMed
18.
Zurück zum Zitat Diesing D, Axt-Fliedner R, Hornung D, Weiss JM, Diedrich K, Friedrich M. Granulomatous mastitis. Arch Gynecol Obstet. 2004;269:233–6.CrossRefPubMed Diesing D, Axt-Fliedner R, Hornung D, Weiss JM, Diedrich K, Friedrich M. Granulomatous mastitis. Arch Gynecol Obstet. 2004;269:233–6.CrossRefPubMed
19.
Zurück zum Zitat Bässler R. Mastitis. Classification, histopathology and clinical aspects. Pathologe. 1997;18:27–36.CrossRefPubMed Bässler R. Mastitis. Classification, histopathology and clinical aspects. Pathologe. 1997;18:27–36.CrossRefPubMed
20.
Zurück zum Zitat Head JF, Elliott RL. Stereotactic radiofrequency ablation: a minimally invasive technique for nonpalpable breast cancer in postmenopausal patients. Cancer Epidemiol. 2009;33:300–5.CrossRefPubMed Head JF, Elliott RL. Stereotactic radiofrequency ablation: a minimally invasive technique for nonpalpable breast cancer in postmenopausal patients. Cancer Epidemiol. 2009;33:300–5.CrossRefPubMed
Metadaten
Titel
Pilot study of radiofrequency ablation therapy without surgical excision for T1 breast cancer: evaluation with MRI and vacuum-assisted core needle biopsy and safety management
verfasst von
Naohito Yamamoto
Hiroshi Fujimoto
Rikiya Nakamura
Manabu Arai
Atsushi Yoshii
Sachiko Kaji
Makiko Itami
Publikationsdatum
01.01.2011
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 1/2011
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-010-0197-6

Weitere Artikel der Ausgabe 1/2011

Breast Cancer 1/2011 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.